Higher toxicity with 42 Gy in 10 fractions as a total dose for 3D-conformal accelerated partial breast irradiation: results from a dose escalation phase II trial
1 Department of Radiation Oncology, Institut Gustave Roussy, 114 rue Edouard Vaillant, 94 805, Villejuif, France
2 Biostatistics and Epidemiology Unit, Institut Gustave Roussy, Villejuif, France
3 Alexandria University, Alexandria, Egypt
4 Physics Unit, Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France
5 Department of Breast Oncology, Institut Gustave Roussy, Villejuif, France
6 Department of Pathology, Institut Gustave Roussy, Villejuif, France
7 Department of Breast Surgery, Institut Gustave Roussy, Villejuif, France
8 Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
9 Grupoimo, Madrid, Spain
Radiation Oncology 2012, 7:141 doi:10.1186/1748-717X-7-141Published: 22 August 2012
Recent recommendations regarding indications of accelerated partial breast irradiation (APBI) have been put forward for selected breast cancer (BC) patients. However, some treatment planning parameters, such as total dose, are not yet well defined. The Institut Gustave Roussy has initiated a dose escalation trial at the 40 Gy/10 fractions/5 days and at a further step of total dose (TD) of 42 Gy/10 fractions/ 5 days. Here, we report early results of the latest step compared with the 40 Gy dose level.
Methods and materials
From October 2007 to March 2010, a total of 48 pT1N0 BC patients were enrolled within this clinical trial: 17 patients at a TD of 42 Gy/10f/5d and 31 at a TD of 40 Gy/10f/5d. Median follow-up was 19 months (min-max, 12–26). All the patients were treated by APBI using a technique with 2 minitangents and an “enface” electrons delivering 20% of the total dose. Toxicities were systematically assessed at 1; 2; 6 months and then every 6 months.
Patients’ recruitment of 42 Gy step was ended owing to persistent grade 3 toxicity 6 months after APBI completion (n = 1). Early toxicities were statistically higher after a total dose of 42 Gy regarding grade ≥2 dry (p = 0.01) and moist (p = 0.05) skin desquamation. Breast pain was also statistically higher in the 42 Gy step compared to 40 Gy step (p = 0.02). Other late toxicities (grade ≥2 fibrosis and telangectasia) were not statistically different between 42 Gy and 40 Gy.
Early toxicities were more severe and higher rates of late toxicities were observed after 42 Gy/10 fractions/5 days when compared to 40 Gy/10 fractions/5 days. This data suggest that 40 Gy/10 fractions/ 5 days could potentially be the maximum tolerance for PBI although longer follow-up is warranted to better assess late toxicities.